On 27 July 2015, Teva Pharmaceutical Industries announced that it has withdrawn its previously announced hostile bid to acquire Mylan N.V. Stibbe represented Mylan in this successful takeover defence and advised Mylan on both litigation and EU competition law-related matters.
On April 8, 2015, Mylan announced that it has made a proposal to acquire Perrigo Company plc in a cash‑and‑stock transaction worth over 25 billion USD. Stibbe represented Mylan in the EU Merger Control proceedings before the European Commission. On 29 July 2015, the European Commission unconditionally approved the transaction under the EU Merger Regulation.
The Stibbe team was led by partners Fons Leijten, Jeroen Kortmann and Rein Wesseling and includes Olivier Schotel on litigation matters; Floris ten Have, Jan Truijens Martinez, Evangelia Demertzi, Dirk de Graeff and Vincent Lampers on EU competition law. On the Teva matter Stibbe worked alongside Cravath Swaine & Moore LLP; NautaDutilh’s litigation team; Arthur Cox; Wilson Sonsini Goodrich & Rosati and Meitar Liquornik Geva Leshem Tal. On the antitrust aspects of the Perrigo matter Stibbe worked alongside Cravath Swaine & Moore LLP.